Previous studies have examined the therapeutic effect of endothelial progenitor cells (EPCs) during the chronic phase of cerebral infarction in rats; however, few studies have investigated the effects of EPCs during the acute phase of infarction. In this study, we evaluated the therapeutic effect of EPCs with low aldehyde dehydrogenase activity (Alde-Low EPCs) in rats with acute cerebral infarction, and our results provide insight that may help to identify a therapeutic mechanism of EPCs for acute cerebral infarction. The administration of Alde-Low EPCs into rats with acute cerebral infarction results in the accumulation and migration of the Alde-Low EPCs into the infarct area and the subsequent decrease of infarct volume. Moreover, we found that the stromal cell-derived factor-1 (SDF-1) and CXC chemokine receptor 4 (CXCR4) signaling pathway may regulate the accumulation of Alde-Low EPCs. The transplantation of Alde-Low EPCs may represent a potential treatment strategy for acute cerebral infarction.
Asahara and colleagues first identified EPCs as a subpopulation of the leukocyte fraction of human peripheral blood [5] . Recent studies have suggested that EPCs contribute to tissue vascularization during both physiological and pathological processes, e.g., wound
healing and cancer, respectively [6, 7] . In particular, there has been a growing interest in EPCs as potential therapeutic agents for ischemic disorders because of their ability to promote recovery after ischemic events, such as hind limb ischemia and myocardial infarction [6] . In stroke, however, EPC studies have been limited [8] .
We have recently identified a population of EPCs derived from umbilical cord blood (UCB) that is suitable for the treatment of ischemic tissue [9] . We divided EPCs into two subpopulations based on the level of their aldehyde dehydrogenase (ALDH) activity and consequently found that EPCs with low ALDH activity (Alde-Low EPCs) possessed a 4 greater ability to proliferate and migrate compared with EPCs with high ALDH activity (Alde-High EPCs). In addition, previous studies have shown that the introduction of Alde-Low EPCs significantly reduced tissue damage in the ischemic condition of a mouse skin flap model [9] .
Here, we confirmed the therapeutic effect of Alde-Low EPCs for acute cerebral infarction using a rat ischemia/reperfusion model.
5

Materials and Methods
Preparation of cells for administration
Alde-Low EPCs, Alde-High EPCs, and human umbilical vein endothelial cells (HUVECs) were prepared as previously described [9] and as briefly summarized below. [10] , and the cells were sorted by FACS. The HUVECs were purchased from Cambrex (Walkersville, MD) and maintained in endothelial cell basal medium 2 (EBM-2; Cambrex).
The cultured HUVECs, Alde-High EPCs, and Alde-Low EPCs were transfected with green fluorescent protein (GFP) as described previously [11] , and the GFP-labeled HUVECs and EPCs were purified using FACSVantage (BD Biosciences, San Jose, CA).
Transient middle cerebral artery occlusion (MCAo) and transarterial cell transplantation
All of the animal experiments were performed in a humane manner following approval from the Animal Experiment Committee of the University of Tsukuba and in accordance with the Regulation for Animal Experiments Committee of the University of Tsukuba.
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Transient middle cerebral artery occlusion (MCAo) model was selected for the similarity with clinical condition during acute phase of ischemia, because reperfusion occured in 20% of patients within 24 hours after MCAo and 80% of patient within seven days [12, 13] .
Male Sprague-Dawley rats weighing 280-320 g were purchased from Charles River Japan Inc. (Yokohama, Japan). The induction of MCAo is an established technique in our laboratory and has been previously described [14] . In brief, after ligation of both the right common carotid artery (CCA) and the external carotid artery, a 4-0 nylon suture (Alfresa Pharma, Osaka, Japan) with silicon coating (Dow Corning Corporation, Midland, MI) on the tip was introduced from the CCA via the internal carotid artery (ICA) into the anterior cerebral artery (ACA) until the origin of middle cerebral artery (MCA) was occluded.
Reperfusion was achieved by withdrawal of the suture following a transient occlusion of the MCA for 60 minutes. A neurological deficit, consisting of a left-sided hemiparesis and
Horner's syndrome on the right side, was evaluated at 30 minutes and 24 hours after reperfusion using the modified Neurological Examination Grading System [15] , and the regional cerebral cortical blood flow (rCoBF) was simultaneously measured trans-cranially using a Laser Doppler flowmeter (ADVANCE, Kyoto, Japan). The neurological deficit and the rCoBF were used as the criteria for a successful ischemic insult.
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Thirty minutes after reperfusion of the MCA, the rats received an injection of HUVECs, Alde-High EPCs, or Alde-Low EPCs (5×10 5 cells) with 0.5 ml of phosphate-buffered saline (PBS) into the CCA via the same route through which the occluded suture was withdrawn. Immunosuppression was induced using an intraperitoneal injection of cyclophosphamide (cyclosporine-A; Wako, Osaka, Japan) at 10 mg/kg body weight 24
hours before and immediately after the transplantation.
Measurement of infarct volume
Twenty-four hours after transplantation, the rats were anesthetized with a lethal dose of intraperitoneal pentobarbital and perfused with PBS via the ascending aorta. The brains were carefully removed and cut into seven serial coronal slices (each 2 mm in thickness) from the frontal pole. These sections were stained with 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C for 30 minutes and imaged to calculate the volume of the infarct areas using SCION Image (SCION Corporation, Frederick, MD). We calculated the ratio of the total infarct area of the seven coronal sections to the contralateral hemisphere (% infarct volume) as the total infarct volume to reduce the distortion of the infarct area by brain edema.
Immunohistochemical and quantitative analysis of GFP-positive cells in the cerebral hemisphere
Twenty-four hours after cell transplantation, the perfused brains were removed as previously described. The brains were cut into 2-mm-thick coronal slices at the level of the caudate-putamen (6-8 mm caudal from the frontal pole); these slices included the MCA perfusion area. The sections were perfused with 4% phosphate-buffered paraformaldehyde The Alde-Low EPCs that had been down-regulated by the CXCR4 shRNA (Alde-Low EPCs CXCR4si) were also transfected with GFP. We evaluated the infarct volume and the accumulation of Alde-Low EPCs CXCR4si 24 hours after cell transplantation, as described above.
Statistical analysis
The values obtained in this study were statistically evaluated using Student's t-test for per-comparison analyses. All of the values are presented as the means ± SD.
Results
Reduction of the infarct volume
Twenty-four hours after the transplantation of EPCs, we examined the infarct lesions, which could be identified as unstained areas by TTC-staining (Fig. 1A-D) . Interestingly, the infarct volume was significantly reduced in the rats of the Alde-Low EPC transplanted group (Fig. 1D ) compared with the PBS, HUVECs, or Alde-High EPC transplanted group (Fig. 1A-C (Fig. 1E) .
Distribution and accumulation of GFP-positive cells
In the Alde-Low EPC transplantation group, a larger number of GFP-positive cells had accumulated on the ischemic side compared with the control side ( Fig. 2A, 2B ), despite the lack of laterality in the distribution of GFP-positive cells in the HUVECs and Alde-High 13 EPC transplanted groups. The GFP-positive cells were detected morphologically as spindle-shaped cells with cytoplasmic GFP fluorescence and nuclear DAPI fluorescence or a round nuclear defect (Fig. 2C-E) . In the Alde-Low EPC transplanted group, we observed scattered groups of GFP-positive cells that were localized within the cerebral parenchyma of the striatum and lateral cortex of the infarct side ( (Fig. 3) .
Involvement of the SDF-1/CXCR4 pathway in the accumulation of Alde-Low EPCs
Fluorescent analysis revealed the expression of SDF-1 in the endothelial cells of capillaries in all the groups, and we found that the GFP-positive cells had accumulated in the capillaries (Fig. 4A) . In addition, in the Alde-Low EPC CXCR4si transplanted group, the number of GFP-positive cells on the infarct side was reduced and the infarct volume had increased compared with the Alde-Low EPC transplanted group (Fig. 4B) . Moreover, the infarct volumes were 53.0% ± 11.8% in the Alde-Low EPC CXCR4si
transplanted group and 37.1 ± 10.4% in the Alde-Low EPCs group (p < 0.05, n = 3) (Fig.   4B ).
Discussion
EPC transplantation therapy shows great promise as a therapeutic option for ischemic disorders because of the ability of EPCs to promote recovery after ischemic events [6, 16] .
However, there have been limited EPC studies investigating the acute phase of stroke [8, 17] . Moreover, the identification and isolation of EPCs have been controversial issues within the research community [18] . EPCs were originally characterized by their cell surface expression of CD34, CD133 and VEGFR-2 [5] ; therefore, EPCs have been predominantly defined based on the expression of cell surface markers. EPCs can be isolated from a variety of sources, such as peripheral blood [19] , bone marrow [17] , spleen [20] , adipose tissue [21, 22] , ES cells [2, 23] , and the UCB [9, 24] . Because of their diverse origins, it has been unclear which type of EPC is the most suitable for cell therapy for stroke and other ischemic disorders.
Some studies examined the therapeutic time window of EPC transplantation during the chronic phase in a model of cerebral ischemia [1] . Another study of autologous mononuclear cell transplantation for cerebral ischemia in rats at 3-72 hours after induction of MCAo reported that the earlier administration of cells was more effective at decreasing the lesion size and increasing the functional outcome [25] . However, few studies have reported on the beneficial effect of EPC transplantation during the acute phase, which is considered to be within 24 hours of transplantation [17, 26] .
In this study, we confirmed that transplantation of Alde-Low EPCs specifically attenuated the infarct volume and that EPCs accumulated in the ischemic region 24 hours after induction of MCAo in rats. These results are consistent with our previous study of Alde-Low EPC transplantation using the mouse skin flap model. However, during the acute phase of ischemia, the therapeutic mechanisms of EPCs remain unclear. During acute phase, trophic factors may also contribute to the therapeutic effects for cerebral ischemia through several different mechanisms, including free radical scavenging, anti-apoptotic activity, and anti-inflammatory activity, thereby reducing secondary brain damage after cerebral infarction [17, 25, 27, 28] .
We found the specific accumulation of Alde-Low EPCs at the ischemic site during the acute phase to be particularly interesting. To investigate the therapeutic mechanism of
Alde-Low EPCs, we investigated the ability of the SDF-1/CXCR4 signaling pathway to mediate the accumulation of Alde-Low EPCs. CXCR4, a 7-transmembrane spanning G-protein-coupled receptor, is expressed on different types of stem cells, progenitor cells, and mature endothelial cells. The chemokine SDF-1 is a proinflammatory cytokine involved in cell trafficking and adhesion and binds exclusively to its cognate receptor,
17
CXCR4 [29, 30, 31] . Many studies have shown that the SDF-1/CXCR4 signaling pathway regulates angiogenesis and vasculogenesis during development via the mobilization, migration and differentiation of EPCs [30, 32, 33] . In addition, SDF-1 is expressed in the ischemic area even during the acute phase [34] . We have previously demonstrated that CXCR4 expression increased significantly in the Alde-Low EPCs compared with the Alde-High or control cells under hypoxic conditions and that Alde-Low EPCs have a higher migratory activity in vitro compared with Alde-High EPCs [9] . Moreover, we used CXCR4 siRNA to specifically block SDF-1/CXCR4 signaling [35, 36] . We confirmed that
Alde-Low EPCs CXCR4si exhibited a reduced ability to accumulate in vivo, strongly suggesting that SDF-1/CXCR4 signaling plays an important role in the accumulation of Alde-Low EPCs during the acute phase of ischemia.
In future studies, we intend to investigate the functional properties of Alde-Low EPCs and investigate the therapeutic mechanism in the sub-acute and chronic phases of infarction in addition to the acute phase.
We demonstrated that a specific subpopulation of EPCs, characterized by low ALDH activity, exerted a therapeutic effect and specifically accumulated in the ischemic area during the acute phase of stroke. We therefore concluded that transplantation of Alde-Low
EPCs might be a promising strategy for the treatment of acute cerebral infarction. However, 
Figure Legends
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We quantified the GFP-positive cells, which were mainly found on the capillaries (D, E).
Specifically in the Alde-Low EPC transplanted group, the migration of GFP-positive cells was observed to be localized within the cerebral parenchyma of the striatum and lateral cortex on the infarct side (F) as well as on the capillaries (E). Scale bars = 50 µm (A, B), 100 µm (C-F). 
